Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Estradiol valerate/dienogest - Bayer Schering Pharma

Drug Profile

Estradiol valerate/dienogest - Bayer Schering Pharma

Alternative Names: BAY 865027; Dienogest/estradiol valerate - Bayer Schering Pharma; DUB Qlaira; DUB-OC; E2/DNG - Bayer Schering Pharma; Natazia; Qlaira; SH T00658; SH T00658ID; SH T00658K; SH T00658L

Latest Information Update: 22 Sep 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bayer Schering Pharma
  • Developer Bayer HealthCare Pharmaceuticals; Bayer HealthCare Pharmaceuticals Inc.
  • Class Estradiol congeners; Estrenes; Hormonal replacements
  • Mechanism of Action Estrogen receptor agonists; Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Metrorrhagia; Pregnancy

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 01 Jun 2015 Bayer completes a phase III trial in Metrorrhagia in China, Philippines, Russia, Singapore, Taiwan and Thailand (NCT01638923)
  • 02 Mar 2015 Estradiol valerate/dienogest is still in a phase III trial for Metrorrhagia in China, Philippines, Russia, Singapore, Taiwan and Thailand (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top